ELOCTATE

Antihemophilic factor, Fc fusion protein, recombinant is approved for patients with hemophilia A for control and prevention of bleeding episodes, management of bleeding during surgical procedures, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. The antihemophilic factor is linked to the Fc protein fragment of antibodies, which prolongs factor circulation in the body and extends time between prophylactic infusions. The product is produced by recombinant DNA technology; no human or animal derived proteins are used in the formulation or purification process. Two dedicated viral clearance steps are also incorporated into the production process. The Altuviiio product has a prolonged half-life (approximately 3-fold) compared to the Eloctate product, allowing for less frequent dosing.

General Administration Information
For storage information, see the specific product information within the How Supplied section.

-Factor VIII activity is expressed in International Units; the actual potency per vial of factor VIII is stated on each vial.
-Plasma factor VIII concentrations can be monitored using either a chromogenic substrate assay (Eloctate only) or a 1-stage clotting assay.

Route-Specific Administration

Injectable Administration
-Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit.
Intravenous Administration
Reconstitution (Altuviiio and Eloctate)

-Use aseptic technique and a flat work surface throughout the entire reconstitution process.
-Allow vial and pre-filled diluent syringe (provided) to reach room temperature.
-Peel back the lid from the vial adapter package. Do not remove the vial adapter from the package or touch the inside of the adapter package.
-Place the vial adapter over the vial. Place the adapter spike directly above the center of the rubber stopper and push the adapter straight down until the spike punctures the center of the vial stopper and is fully inserted. Discard package cover.
-Hold the plunger rod at the circular disk on the end and place the tip of the plunger rod into the end of the syringe. Turn the plunger rod to the right until it is securely attached. Only use the provided diluent syringe.
-Hold diluent syringe with 1 hand by the ridged part directly under cap with cap pointing up. Do not use if the cap has been removed or is not securely attached. Grasp the cap with the other hand and bend it at a 90-degree angle until it snaps off. Do not touch the glass tip of the syringe or the inside of the cap.
-Insert the tip of the syringe into the adapter opening and turn the syringe to the right until it is securely attached to the adapter. Slowly depress the plunger rod to inject all the diluent into the vial. The plunger rod may rise slightly after this process.
-With the syringe still connected to the adapter, gently swirl the vial until the product is completely dissolved. The final solution should be clear to slightly opalescent and colorless. Do not shake. Do not use the reconstituted solution if it contains visible particles or is cloudy.
-Completely depress the plunger rod. Turn the vial upside-down and slowly pull on the plunger rod to draw the solution into the syringe. Be careful not to pull the plunger rod completely out of the syringe.
-Gently unscrew the syringe from the vial adapter and dispose of the vial with the adapter still attached. Do not touch the syringe tip or the inside of the cap.
-If combining 2 or more vials, leave the vial adapter attached to the vial. Do not detach the diluent syringe or the large luer lock syringe until ready to attach the large luer lock syringe to the next vial (with vial adapter attached). Remove the diluent syringe from the vial adapter until it is completely detached. Use a larger luer lock plastic syringe to combine the contents of the reconstituted vials into the syringe. Repeat this pooling procedure with each vial necessary to obtain the required dose.
-Storage: Use the reconstituted solution as soon as possible, but no later than 3 hours after reconstitution. Do not touch the glass tip of the syringe if not used immediately after reconstitution. Protect from direct sunlight. Do not refrigerate after reconstitution.

Intermittent IV Infusion

-Do not administer reconstituted solution in the same tubing or container with other medications.
-Attach the syringe to the connector end of the infusion set tubing by turning it to the right until it is securely attached. Push the plunger rod until all air is removed from the syringe and solution has filled the infusion set needle. Do not push solution through the needle. Remove the protective needle cover from the infusion set needle.
-Altuviiio: Administer via intravenous bolus infusion at a rate of administration determined by the patient's comfort level, and no faster than the below recommendations for age/weight:-Adults and Adolescents: Administer each vial over 1 to 2 minutes.
-Pediatric patients weighing 20 kg or more: Administer each vial over 2 to 3 minutes.
-Pediatric patients weighing less than 20 kg: Administer each vial over 6 minutes.

-Eloctate: Administer via intravenous bolus infusion at a rate of administration determined by the patient's comfort level, and no faster than 10 mL/minute.

Hypersensitivity reactions, including anaphylactoid reactions, are possible with recombinant antihemophilic factor Fc fusion protein. Early signs of hypersensitivity reactions include angioedema, chest tightness, dyspnea, wheezing, urticaria, and pruritus. Rash was reported in 0.7% to 1% of pediatric and adult patients during clinical trials of recombinant antihemophilic factor Fc fusion protein. Two patients were withdrawn from the study due to rash and joint pain. Discontinue recombinant antihemophilic factor Fc fusion protein if hypersensitivity symptoms occur, and initiate appropriate treatment.

Antibody formation, including neutralizing antibodies (inhibitors), to factor VIII can occur after the administration of recombinant antihemophilic factor Fc fusion protein. In clinical trials in previously untreated patients (n = 103), development of neutralizing antibodies (inhibitors) was observed in 28 patients; 14 of them had a high-titer inhibitor. Based on patients with an inhibitor test after an exposure day (ED) milestone or who developed an inhibitor at any time during the study, the incidence of factor VIII inhibitor development was 28/90 patients (31.1%) with at least 10 EDs and 28/86 patients (32.6%) with at least 50 EDs. The median time to inhibitor development for the 28 patients was 9 EDs (interquartile range: 6.5 to 12). During treatment (up to 49.64 weeks) in the clinical studies of another recombinant antihemophilic factor Fc fusion protein product, 4/277 (2.2%) patients developed anti-drug antibodies (ADAs). There was no impact of ADAs on factor VIII activity-time profiles, pharmacokinetic exposure parameters, bleeding episodes, or pharmacodynamic response. No patients developed neutralizing antibodies. The observed incidence of ADAs is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADAs in various studies or between different factor VIII products.

Arthralgia (16%) and back pain (6%) were among the most common adverse reactions reported in adolescents and adults during clinical trials (n = 159) of recombinant antihemophilic factor Fc fusion protein. In clinical trials with another recombinant antihemophilic factor Fc fusion protein product in pediatric and adult patients, malaise, myalgia, and arthralgia were reported in 2 of 276 patients (0.7%). Other musculoskeletal and general adverse reactions reported in 1 of 276 patients (0.4%) include joint swelling, back pain, and feeling hot or cold. Two patients were withdrawn from the study due to rash and arthralgia.

Headache (21%) was one of the most common adverse reactions reported in adolescents and adults during clinical trials (n = 159) of recombinant antihemophilic factor Fc fusion protein. In the ongoing pediatric safety study (n = 67), headache was reported in 1% of patients receiving antihemophilic factor Fc fusion protein. In clinical trials (n = 276) with another recombinant antihemophilic factor Fc fusion protein product in pediatric and adult patients, headache (0.7%), dysgeusia (0.4%), and dizziness (0.4%) were reported.

Lower abdominal pain was reported in 1 out of 276 patients (0.4%) during clinical trials of recombinant antihemophilic factor Fc fusion protein in pediatric and adult patients.

Cardiovascular-related adverse reactions reported in 1 of 276 patients (0.4%) during clinical trials of recombinant antihemophilic factor Fc fusion protein in pediatric and adult patients included bradycardia, hypertension, procedural hypotension, hot flush, and chest pain (unspecified).

Cough was reported in 1 of 276 patients (0.4%) during clinical trials of recombinant antihemophilic factor Fc fusion protein in pediatric and adult patients.

Injection site reaction, manifested as infusion site pain, was reported in 1 of 276 patients (0.4%) during clinical trials of recombinant antihemophilic factor Fc fusion protein in pediatric and adult patients.

Device-related thrombosis, including deep vein thrombosis, was reported in 1.9% (n = 2/103) of previously untreated patients receiving recombinant antihemophilic factor Fc fusion protein during clinical trials. In the long term safety extension study of another recombinant antihemophilic factor Fc fusion protein product, thromboembolic events (unspecified) occurred in 1% (n = 3/206) of patients; however, these 3 patients had pre-existing risk factors.

Factor VIII inhibitors can develop in patients receiving recombinant antihemophilic factor Fc fusion protein. Monitor all patients for the development of factor VIII inhibitors utilizing appropriate clinical observations and laboratory tests. Consider the presence of inhibitors if the expected factor VIII activity concentrations in plasma are not attained or if bleeding is not controlled with the recommended dose of antihemophilic factor Fc fusion protein.

If central venous catheter placement is required, consider the risks of complications including local infections, bacteremia, and thrombosis. Catheter-related thrombosis, including deep vein thrombosis, has been reported in patients receiving recombinant antihemophilic factor Fc fusion protein.

Once clotting has been normalized by treatment with recombinant antihemophilic factor Fc fusion protein, hemophilic patients with cardiovascular risk factors or cardiac disease may be at the same risk to develop cardiovascular events as non-hemophilic patients.

If assessment of plasma factor VIII activity is needed in patients receiving Altuviiio, use a validated 1-stage clotting assay. Use of a chromogenic assay and a specific ellagic acid based aPTT reagent in 1-stage clotting assay may result in laboratory test interference. Specifically, these assays may overestimate the factor VIII activity by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's factor VIII activity. Use of a reference laboratory is recommended when a qualified 1-stage clotting assay or chromogenic assay is not available locally. For Eloctate, plasma factor VIII activity can be monitored using either a chromogenic assay or a 1-stage clotting assay routinely used in US clinical laboratories.

There are no data regarding recombinant antihemophilic factor Fc fusion protein use in pregnant women to inform a drug-associated risk. Animal reproductive and developmental toxicity studies have not been conducted. In a placental transfer study, antihemophilic factor Fc fusion protein was detected in murine fetal blood at approximately 1% of the maternal blood concentrations, 3 to 4 hours after a dose 260 to 650 times the clinical human dose. Administer antihemophilic factor Fc fusion protein during pregnancy only if clearly needed. If administered, advise the patient that the risks to the mother and fetus are unknown.

There are no data on the presence of antihemophilic factor Fc fusion protein in human milk, the effects on the breast-fed infant, or the effects on milk production. Consider the benefits of breast-feeding along with the mother's clinical need for antihemophilic factor Fc fusion protein, and any potential adverse effects on the breast-fed infant from antihemophilic factor Fc fusion protein or the underlying maternal condition.

-Dosage and duration of treatment for all antihemophilic factor products depend on the severity of the factor VIII deficiency, the location and extent of bleeding, the patient's clinical condition, age, and recovery of factor VIII. For all these reasons, titrate dosages to the patient's clinical response.
-Each vial label states the factor VIII potency in International Units. One International Unit corresponds to the activity of factor VIII contained in 1 mL of normal human plasma.
-Recombinant antihemophilic factor Fc fusion protein is not indicated for the treatment of von Willebrand disease.
-Generally, 1 International Unit/kg increases the circulating factor VIII by 2 International Units/dL. Carefully monitor clinical effects and adjust dosage and/or frequency as needed. The following formulas may be used to estimate the required dose or the desired in vivo peak increase in factor VIII concentration: Dose (International Units) = Body Weight (kg) x Desired factor VIII Rise (International Units/dL or % of normal) x 0.5 (International Units/kg per International Units/dL) or Estimated Increment of factor VIII (International Units/dL or % of normal) = [Total Dose (International Units)/Body Weight (kg)] x 2 (International Units/dL per International Units/kg).

For the on-demand treatment and control of hemorrhage in patients with hemophilia A (classical hemophilia):
-for control of minor and moderate bleeding (e.g., uncomplicated joint bleeds, minor muscle bleeds, oral bleeds) in patients with hemophilia A:
NOTE: For minor or moderate bleeding, the circulating factor VIII activity required is 40% to 60% of normal.
Intravenous dosage (Altuviiio):
Adults: 50 International Units/kg/dose IV as a single dose. For minor and moderate bleeding episodes occurring within 2 to 3 days after a prophylactic dose, a lower dose of 30 International Units/kg/dose IV may be used. May give additional doses of 30 or 50 International Units/kg/dose IV every 2 to 3 days if needed.
Infants, Children, and Adolescents: 50 International Units/kg/dose IV as a single dose. For minor and moderate bleeding episodes occurring within 2 to 3 days after a prophylactic dose, a lower dose of 30 International Units/kg/dose IV may be used. May give additional doses of 30 or 50 International Units/kg/dose IV every 2 to 3 days if needed.
Intravenous dosage (Eloctate):
Adults: 20 to 30 International Units/kg/dose IV every 24 to 48 hours until bleeding is resolved.
Children and Adolescents 6 to 17 years: 20 to 30 International Units/kg/dose IV every 24 to 48 hours until bleeding is resolved.
Infants and Children 1 to 5 years: 20 to 30 International Units/kg/dose IV every 12 to 24 hours until bleeding is resolved.
-for control of major bleeding (e.g., life- or limb-threatening, intracranial, gastrointestinal, retroperitoneal, deep muscle with neurovascular injury) in patients with hemophilia A:
NOTE: For major bleeding, the circulating factor VIII activity required is 80% to 100% of normal.
Intravenous dosage (Altuviiio):
Adults: 50 International Units/kg/dose IV as a single dose. May give additional doses of 30 or 50 International Units/kg/dose IV every 2 to 3 days if needed.
Infants, Children, and Adolescents: 50 International Units/kg/dose IV as a single dose. May give additional doses of 30 or 50 International Units/kg/dose IV every 2 to 3 days if needed.
Intravenous dosage (Eloctate):
Adults: 40 to 50 International Units/kg/dose IV every 12 to 24 hours until bleeding is resolved (approximately 7 to 10 days).
Children and Adolescents 6 to 17 years: 40 to 50 International Units/kg/dose IV every 12 to 24 hours until bleeding is resolved (approximately 7 to 10 days).
Infants and Children 1 to 5 years: 40 to 50 International Units/kg/dose IV every 8 to 24 hours until bleeding is resolved (approximately 7 to 10 days).

For the perioperative management of surgical bleeding in patients with hemophilia A:
-for the perioperative management of surgical bleeding with minor surgery (e.g., uncomplicated dental extraction):
NOTE: For minor surgery, the circulating factor VIII activity required is 50% to 80% of normal.
Intravenous dosage (Altuviiio):
Adults: 50 International Units/kg/dose IV as a single dose preoperatively. May give an additional dose of 30 or 50 International Units/kg/dose IV after 2 to 3 days if needed.
Infants, Children, and Adolescents: 50 International Units/kg/dose IV as a single dose preoperatively. May give an additional dose of 30 or 50 International Units/kg/dose IV after 2 to 3 days if needed.
Intravenous dosage (Eloctate):
Adults: 25 to 40 International Units/kg/dose IV every 24 hours; continue for at least 1 day until wound healing is achieved.
Children and Adolescents 6 to 17 years: 25 to 40 International Units/kg/dose IV every 24 hours; continue for at least 1 day until wound healing is achieved.
Infants and Children 1 to 5 years: 25 to 40 International Units/kg/dose IV every 12 to 24 hours; continue for at least 1 day until wound healing is achieved.
-for the perioperative management of surgical bleeding with major surgery (e.g., intracranial, intra-abdominal, joint replacement surgery, complicated dental procedures):
NOTE: for major surgery, the circulating factor VIII activity required is 80% to 120% of normal.
Intravenous dosage (Altuviiio):
Adults: 50 International Units/kg/dose IV as a single dose preoperatively. May give additional doses of 30 or 50 International Units/kg/dose IV every 2 to 3 days as clinically needed.
Infants, Children, and Adolescents: 50 International Units/kg/dose IV as a single dose preoperatively. May give additional doses of 30 or 50 International Units/kg/dose IV every 2 to 3 days as clinically needed.
Intravenous dosage (Eloctate):
Adults: 40 to 60 International Units/kg/dose IV as a single dose preoperatively, followed by 40 to 50 International Units/kg/dose IV after 8 to 24 hours. Repeat every 24 hours until adequate wound healing and then continue for at least 7 days to maintain a factor VIII activity within the target range.
Children and Adolescents 6 to 17 years: 40 to 60 International Units/kg/dose IV as a single dose preoperatively, followed by 40 to 50 International Units/kg/dose IV after 8 to 24 hours. Repeat every 24 hours until adequate wound healing and then continue for at least 7 days to maintain a factor VIII activity within the target range.
Infants and Children 1 to 5 years: 40 to 60 International Units/kg/dose IV as a single dose preoperatively, followed by 40 to 50 International Units/kg/dose IV after 6 to 24 hours. Repeat every 24 hours until adequate wound healing and then continue for at least 7 days to maintain a factor VIII activity within the target range.

For routine bleeding prophylaxis to prevent or reduce the frequency of bleeding episodes:
Intravenous dosage (Altuviiio):
Adults: 50 International Units/kg/dose IV once weekly.
Infants, Children, and Adolescents: 50 International Units/kg/dose IV once weekly.
Intravenous dosage (Eloctate):
Adults: 50 International Units/kg/dose IV every 4 days initially. Adjust dose based on response. The typical dosing range is 25 to 65 International Units/kg/dose IV every 3 to 5 days.
Children and Adolescents 6 to 17 years: 50 International Units/kg/dose IV every 4 days initially. Adjust dose based on response. The typical dosing range is 25 to 65 International Units/kg/dose IV every 3 to 5 days.
Infants and Children 1 to 5 years: 50 International Units/kg/dose IV twice weekly initially. Adjust dose based on response. The typical dosing range is 25 to 65 International Units/kg/dose IV every 3 to 5 days. More frequent or higher doses up to 80 International Units/kg/dose IV may be needed in some patients.

Therapeutic Drug Monitoring:
-Monitor plasma factor VIII activity by performing a validated test (e.g., one-stage clotting assay or chromogenic assay [Eloctate only]) to confirm adequate factor VIII concentrations have been achieved and maintained.
-To determine whether factor VIII inhibitors are present, perform a Bethesda assay. The presence of inhibitors should be suspected if the expected factor VIII activity concentrations in plasma are not attained or if bleeding is not controlled with the recommended dose of recombinant antihemophilic factor Fc fusion protein. Use Bethesda Units (BU) to report inhibitor concentrations.

Maximum Dosage Limits:
Specific maximum dosage information is not available. Individualize dosage based on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient's age and clinical condition.

Patients with Hepatic Impairment Dosing
Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.

Patients with Renal Impairment Dosing
Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.

*non-FDA-approved indication

There are no drug interactions associated with Antihemophilic Factor, Fc Fusion Protein, Recombinant products.

In patients with hemophilia A, there is a deficiency of functional coagulation factor VIII (FVIII) leading to a prolonged clotting time in the activated partial thromboplastin time (aPTT) assay. Administration of recombinant antihemophilic factor Fc fusion protein normalizes the aPTT over the effective dosing period. Antihemophilic factor Fc fusion protein is a fully recombinant, fusion protein that temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. Antihemophilic factor Fc fusion protein contains the Fc region of human IgG1, which binds to the neonatal Fc receptor (FcRn). FcRn is part of a naturally occurring pathway that delays lysosomal degradation of immunoglobulins by cycling them back into circulation and prolonging their plasma half-life.

Mechanism of half-life extension with Altuviiio
Altuviiio is a recombinant FVIII analogue fusion protein that is independent of endogenous von Willebrand factor (VWF) in order to overcome the half-life limit imposed by FVIII-VWF interactions. The D'D3 domain of VWF is the region that interacts with FVIII. Appending the D'D3 domain of VWF to a recombinant FVIII-Fc fusion protein provides protection and stability to FVIII, and prevents FVIII interaction with endogenous VWF, thus overcoming the limitation on FVIII half-life imposed by VWF clearance. Altuviiio contains 2 XTEN polypeptides, which alter the hydrodynamic radius of the fusion protein, thus reducing rates of clearance and degradation, and improving pharmacokinetic properties. In Altuviiio, the natural FVIII B domain (except 5 amino acids) is replaced with the first XTEN, inserted in between FVIII N745 and E1649 amino acid residues, and the second XTEN is inserted in between the D'D3 domain and Fc.

Recombinant antihemophilic factor Fc fusion protein is administered intravenously. Pharmacokinetic parameters obtained in clinical studies with both products were based on plasma factor VIII activity measured by the 1-stage clotting assay. Altuviiio has demonstrated 3- to 4-fold prolonged half-life relative to other standard and extended half-life factor VIII products.

Altuviiio
The pharmacokinetics of Altuviiio were evaluated in clinical studies in adult patients (n = 134) receiving weekly IV doses of 50 International Units/kg. After a single dose of 50 International Units/kg, Altuviiio exhibited high sustained factor VIII activity with prolonged half-life across age cohorts. The pharmacokinetic profile at steady state (Week 26) was comparable with the pharmacokinetic profile obtained after the first dose. The factor VIII activity over 10 International units/dL was maintained in 83.5% of adults throughout the study.
-Vd (mL/kg)-Adults: 31

-AUC (International Units x hours/dL)-Adults: 9,850

-t1/2 (hours)-Adults: 48.2

-CL (mL/hour/kg)-Adults: 0.493

-IR (International Units/dL per International Units/kg)
-Adults: 2.64


Eloctate
The pharmacokinetics of Eloctate were evaluated in clinical studies in adult patients (n = 26) receiving a single 50 International Unit/kg/dose. The pharmacokinetic profile at steady state (Week 14) was comparable with the pharmacokinetic profile obtained after the first dose.
-Vd (mL/kg)-Adults: 49.5

-AUC/dose (International Units x hour/dL per International Units/kg)-Adults: 54.1

-t1/2 (hours)-Adults: 19.7

-CL (mL/hour/kg)-Adults: 2.06

-IR (International Units/dL per International Units/kg)-Adults: 2.26


Affected cytochrome P450 isoenzymes: none


-Special Populations
Pediatrics
Altuviiio
The pharmacokinetics of Altuviiio were evaluated in clinical studies in pediatric patients 1 to 17 years (n = 57) receiving weekly IV doses of 50 International Units/kg. Among children younger than 12 years, 32 subjects had Altuviiio single dose pharmacokinetic profiles available. After a single dose of 50 International Units/kg, Altuviiio exhibited high sustained factor VIII activity with prolonged half-life across age cohorts. There was a trend toward increasing AUC and decreasing clearance, with increasing age in the pediatric cohorts. The pharmacokinetic profile at steady state (Week 26) was comparable with the pharmacokinetic profile obtained after the first dose. The factor VIII activity over 10 International units/dL was maintained in 83.5% of adolescents throughout the study. In children younger than 12 years, Altuviiio maintained normal to near normal (more than 40 International units/dL) factor VIII activity for 2 to 3 days and more than 10 International units/dL factor VIII activity for approximately 6 to 7 days. The majority of children younger than 12 years maintained factor VIII activity in mild hemophilia range (more than 5 International units/dL) 7 days after the dosing.
-Vd (mL/kg)-Children 1 to 5 years: 38
-Children 6 to 11 years: 38.1
-Children and Adolescents 12 to 17 years: 34.9

-AUC (International Units x hours/dL)-Children 1 to 5 years: 6,710
-Children 6 to 11 years: 7,190
-Children and Adolescents 12 to 17 years: 8,350

-t1/2 (hours)-Children 1 to 5 years: 39.9
-Children 6 to 11 years: 42.4
-Children and Adolescents 12 to 17 years: 44.6

-CL (mL/hour/kg)-Children 1 to 5 years: 0.74
-Children 6 to 11 years: 0.681
-Children and Adolescents 12 to 17 years: 0.582

-IR (International Units/dL per International Units/kg)-Children 1 to 5 years: 2.1
-Children 6 to 11 years: 2.17
-Children and Adolescents 12 to 17 years: 2.25

Eloctate
The pharmacokinetics of Eloctate were evaluated in clinical studies in pediatric patients 1 to 17 years (n = 65) receiving a single 50 International Unit/kg/dose. The bodyweight-adjusted clearance (CL) was 75% higher in children 1 to 5 years compared to adolescents and adults. This may result in a need for more frequent and/or higher dosing based on body weight in children 1 to 5 years. Pharmacokinetic parameters of subjects 6 to 17 years of age are similar to those of adults, and an age-based dose adjustment is not required in patients 6 years of age and older. The pharmacokinetic profile at steady state (Week 14) was comparable with the pharmacokinetic profile obtained after the first dose.
-Vd (mL/kg)-Children 1 to 5 years: 58.6
-Children 6 to 11 years: 52.1
-Children and Adolescents 12 to 17 years: 60.3

-AUC/dose (International Units x hour/dL per International Units/kg)-Children 1 to 5 years: 30
-Children 6 to 11 years: 41.9
-Children and Adolescents 12 to 17 years: 38.7

-t1/2 (hours)-Children 1 to 5 years: 12.7
-Children 6 to 11 years: 14.9
-Children and Adolescents 12 to 17 years: 16.4

-CL (mL/hour/kg)-Children 1 to 5 years: 3.6
-Children 6 to 11 years: 2.78
-Children and Adolescents 12 to 17 years: 2.66

-IR (International Units/dL per International Units/kg)-Children 1 to 5 years: 1.92
-Children 6 to 11 years: 2.44
-Children and Adolescents 12 to 17 years: 1.85


Gender Differences
The pharmacokinetics of recombinant antihemophilic factor Fc fusion protein are not significantly influenced by gender.

Ethnic Differences
The pharmacokinetics of recombinant antihemophilic factor Fc fusion protein are not significantly influenced by race.

Other
The pharmacokinetics of recombinant antihemophilic factor Fc fusion protein are not significantly influenced by von Willebrand factor (VWF) antigen activity (40 to 339 International Units/dL), hematocrit concentration (28% to 57%), blood type, HCV status, or HIV status.